Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX

Fisher Asset Management LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 5.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 822,208 shares of the biopharmaceutical company’s stock after selling 49,420 shares during the period. Fisher Asset Management LLC owned 1.24% of Celldex Therapeutics worth $16,732,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Nuveen LLC bought a new position in shares of Celldex Therapeutics in the first quarter valued at $7,789,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Celldex Therapeutics in the 2nd quarter worth about $7,894,000. Millennium Management LLC lifted its position in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after acquiring an additional 306,330 shares in the last quarter. American Century Companies Inc. lifted its position in Celldex Therapeutics by 24.7% in the 2nd quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock valued at $15,873,000 after acquiring an additional 154,664 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Celldex Therapeutics by 5.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock valued at $34,050,000 after purchasing an additional 83,174 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CLDX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Citigroup cut their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Mizuho initiated coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 price objective for the company. Wells Fargo & Company dropped their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. Finally, HC Wainwright cut their target price on Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.80.

Insider Buying and Selling at Celldex Therapeutics

In related news, insider Richard M. Wright sold 49,298 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the transaction, the insider owned 20,833 shares of the company’s stock, valued at $499,992. This represents a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.40% of the company’s stock.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $27.81 on Thursday. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $29.05. The stock’s fifty day moving average price is $25.96 and its two-hundred day moving average price is $23.45. The company has a market cap of $1.85 billion, a P/E ratio of -8.23 and a beta of 1.13.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. On average, analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.